P787: Use of upadacitinib to treat IBD in post-liver transplantECCO'24Year: 2024
Authors: Miyatani, Y.(1)*;Choi, D.(1);Choi, N.K.(1);Aronsohn, A.I.(2);Pillai, A.(2);Cohen, R.D.(1);Rubin, D.T.(1);
(1)University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;(2)University of Chicago Medicine, Center for Liver Diseases, Chicago, United States;
P788: The effect of etrasimod on faecal calprotectin and high-sensitivity C-reactive protein: Results from the ELEVATE UC clinical programmeECCO'24Year: 2024
Authors: Jairath, V.(1);Rubin, D.T.(2);Verstockt, B.(3,4);Çekin, A.H.(5);Abreu, M.T.(6);Lees, C.W.(7,8);Fellmann, M.(9);Woolcott, J.C.(10);Crosby, C.(11);Wu, J.(12);Bhattacharjee, A.(13);Herman, D.(11);Gu, G.(11);Siegmund, B.(14,15)*;
(1)Western University, Department of Medicine and Department of Epidemiology and Biostatistics, London- ON, Canada;(2)University of Chicago Medicine Inflammatory Bowel Disease Center, Section of Gastroenterology- Hepatology and Nutrition, Chicago- IL, United States;(3)University Hospitals Leuven- KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(4)Translational Research in GI Disorders- KU Leuven, Department of Chronic Diseases and Metabolism, Leuven, Belgium;(5)University of Health Sciences Antalya Training and Research Hospital, Department of Gastroenterology, Antalya, Turkey;(6)University of Miami Miller School of Medicine, Department of Medicine- Division of Gastroenterology- Crohn’s and Colitis Center, Miami- FL, United States;(7)University of Edinburgh, Institute of Genetics & Molecular Medicine, Edinburgh, United Kingdom;(8)Western General Hospital- NHS Lothian, Edinburgh IBD Unit, Edinburgh, United Kingdom;(9)., Pfizer AG, Zürich, Switzerland;(10)., Pfizer Inc, Collegeville- PA, United States;(11)., Pfizer Inc, La Jolla- CA, United States;(12)., Pfizer Inc, Cambridge- MA, United States;(13)., Pfizer Healthcare India Pvt. Ltd, Chennai, India;(14)Charité-Universitätsmedizin Berlin, Med. Klinik für Gastroenterologie- Infektiologie- Rheumatologie, Berlin, Germany;(15)., Freie Universität Berlin- Humboldt-Universität zu Berlin- Campus Benjamin Franklin, Berlin, Germany;
P789: Impact of risk factors for Janus kinase inhibitor use identified by the Pharmacovigilance Risk Assessment Committee on the safety and efficacy of ozanimod in patients with moderately to severely active ulcerative colitisECCO'24Year: 2024
Authors: Siegmund, B.(1)*;Kuehbacher, T.(2);Armuzzi, A.(3);Hart, A.(4);Bressler, B.(5);Feagan, B.G.(6);Wu, H.(7);Ahmad, H.A.(7);Osterman, M.T.(7);Charles, L.(7);Poehler, A.M.(8);Jain, A.(7);Danese, S.(9);
(1)Charité – Universitätsmedizin Berlin, Gastroenterology- Infectiology and Rheumatology, Berlin, Germany;(2)St. Marien- and St. Annastiftskrankenhaus Hospital- Ludwigshafen am Rhein- Academic Medical Hospital of Mannheim- Heidelberg University, Internal Medicine and Gastroenterology, Ludwigshafen am Rhein, Germany;(3)IBD Center- IRCCS Humanitas Research Hospital- Rozzano- Milan- Italy- and Department of Biomedical Sciences- Humanitas University- Pieve Emanuele, Inflammatory Bowel Disease and Biomedical Sciences, Rozzano, Italy;(4)St Mark@E@s Hospital and Imperial College, Gastroenterology, London, United Kingdom;(5)University of British Columbia, Medicine, Vancouver, Canada;(6)Robarts Research Institute- Western University, Inflammatory Bowel Diseases, London, Canada;(7)Bristol Myers Squibb, n/a, Princeton, United States;(8)Bristol Myers Squibb, n/a, Munich, Germany;(9)Department of Gastroenterology and Endoscopy- IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Gastroenterology and Endoscopy, Milan, Italy;
P790: Assessment of steroid use in patients with active ulcerative colitis who initiated a new Janus kinase inhibitor or tumour necrosis factor inhibitor using data from a United States claims databaseECCO'24Year: 2024
Authors: Dubinsky, M.C.(1)*;Gianfrancesco, M.(2);Gauthier, G.(3);Fallon, L.(3);Lichtenstein, G.R.(4);Khan, N.H.(4);Melmed, G.Y.(5);Hanauer, S.(6);Ritter, T.(7);Bell, G.(2);Lee, Y.C.(2);Kulisek, N.(8);Yndestad, A.(9);Rubin, D.T.(10);
(1)Icahn School of Medicine at Mount Sinai, Susan and Leonard Feinstein IBD Center, New York- NY, United States;(2)-, Pfizer Inc, New York- NY, United States;(3)-, Pfizer Canada ULC, Kirkland- QC, Canada;(4)Perelman School of Medicine at the University of Pennsylvania, Division of Gastroenterology, Philadelphia- PA, United States;(5)Cedars-Sinai Medical Center, Division of Gastroenterology- Department of Medicine, Los Angeles- CA, United States;(6)Northwestern University Feinberg School of Medicine, Department of Medicine, Chicago- IL, United States;(7)-, GI Alliance, Southlake- TX, United States;(8)-, Pfizer Inc, Collegeville- PA, United States;(9)-, Pfizer Inc, Oslo, Norway;(10)University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago- IL, United States;
P791: Trends in gender representation in inflammatory bowel disease randomized trials from 1955-2023ECCO'24Year: 2024
Authors: Gros, B.(1,2)*;Bassi, M.(3);Sleiman, J.(4);Charabaty, A.(5);
(1)Western General Hospita, Edinburgh IBD Unit, Edinburgh, United Kingdom;(2)Reina Sofía University Hospital, Gastroenterology and Hepatology, Cordoba, Spain;(3)Saint Peter@E@s University Hospital/Rutgers University, Gastroenterology and Hepatology, New Jersey, United States;(4)University of Pittsburgh Medical Center, Gastroenterology- Hepatology and Nutrition, Pennsylvania, United States;(5)Johns Hopkins School of Medicine, Gastroenterology and Hepatology, Washington, United States;
P792: Real-world evidence comparison of the effectiveness of ustekinumab with anti-TNF or vedolizumab in ulcerative colitis: 1-year maintenance therapy results from the prospective, observational RUN-UC studyECCO'24Year: 2024
Authors: Bokemeyer, B.(1,2)*;Plachta-Danielzik, S.(3);Howaldt, S.(4);Mohl, W.(5);Efken, P.(6);Ehehalt, R.(7);Kahl, M.(8);Krause, T.(9);Trentmann, L.(10);Lügering, A.(11);Schnoy, E.(12);Jochum, C.(13);Fajardo Salmon, S.(3);Hartmann, P.(14);Gilman, E.(3);Schreiber, S.(15);
(1)Interdisciplinary Crohn Colitis Centre Minden, Gastroenterology, Minden, Germany;(2)University Hospital Schleswig-Holstein Campus Kiel, Clinic of General Internal Medicine I, Minden, Germany;(3)Competence Network IBD, Study Department, Kiel, Germany;(4)Gastroenterology Practice Hamburg, Gastroenterology, Hamburg, Germany;(5)Center for Gastroenterology Saar MVZ- Saarbruecken- Germany, Gastroenterology, Saarbrücken, Germany;(6)Gastroenterology Practice Minden, Gastroenterology, Minden, Germany;(7)Gastroenterology Practice Heidelberg, Gastroenterology, Heidelberg, Germany;(8)Practice for Internal Medicine, Gastroenterology, Hamburg, Germany;(9)Gastroenterology Practice Kassel, Gastroenterology, Kassel, Germany;(10)Gastroenterology Practice Bremen, Gastroenterology, Bremen, Germany;(11)Gastroenterology Practice Münster, Gastroenterology, Münster, Germany;(12)University Hospital of Augsburg- Augsburg- Germany, III. Medical Clinic, Augsburg, Germany;(13)University Hospital Charité Berlin – Campus Mitte- Berlin- Germany, Department of Hepatology and Gastroenterology-, Berlin, Germany;(14)Gastroenterology Practice Minden, Study Department, Minden, Germany;(15)University Hospital Schleswig-Holstein Campus Kiel, Clinic of General Internal Medicine I, Kiel, Germany;
P793: Efficacy and safety of probiotics in inflammatory bowel disease: an umbrella review and updated meta-analysis of randomized controlled trialsECCO'24Year: 2024
Authors: Estevinho, M.M.(1)*;Rodriguez-Lago, I.(2);Dias, C.C.(3);Barreiro-de Acosta, M.(4);Magro, F.(5);
(1)Centro Hospitalar Vila Nova de Gaia/Espinho, Gastroenterology, Vila Nova de Gaia, Portugal;(2)Hospital Universitario de Galdakao, Gastroenterology, Bilbao, Spain;(3)Faculty of Medicine University of Porto, Medical Decision Tools and Biostatistics, Porto, Portugal;(4)Hospital Clínico Universitario de Santiago, Gastroenterology, Santiago de Compostela, Spain;(5)Centro Hospitalar de São João, Gastroenterology, Porto, Portugal;
P794: Relationship between Ustekinumab Trough Concentrations and Clinical, Biochemical and Endoscopic Outcomes in Crohn’s Disease; A Multi-Center Nationwide Study (TARGET STUDY)ECCO'24Year: 2024
Authors: Shehab, M.(1)*;Alrashed, F.(2);Abdullah, I.(1);Alfadhli, A.(1);
(1)Mubarak Al-Kabeer Hospital, Internal medicine, Kuwait, Kuwait;(2)Kuwait University, Pharmacy Practice, Aljabreyah, Kuwait;
P795: Efficacy and safety of etrasimod as a first-line advanced treatment following 5-aminosalicylic acid and/or thiopurines: Data from the ELEVATE UC 52 and ELEVATE UC 12 phase 3 clinical trialsECCO'24Year: 2024
Authors: Sonnenberg, E.(1)*;Lees, C.W.(2,3);Baert, F.(4);Piperni, C.(5);Wu, J.(6);Bhattacharjee, A.(7);Wosik, K.(8);Marshall, J.K.(9);
(1)Charité-Universitätsmedizin Berlin, Medizinische Klinik m. S. Gastroenterologie- Infektiologie und Rheumatologie, Berlin, Germany;(2)., Institute of Genetics & Molecular Medicine- University of Edinburgh, Edinburgh, United Kingdom;(3)Western General Hospital- NHS Lothian, Edinburgh IBD Unit, Edinburgh, United Kingdom;(4)AZ Delta, Department of Gastroenterology, Roeselare, Belgium;(5)., Pfizer Canada, Kirkland- QC, Canada;(6)., Pfizer Inc, Cambridge- MA, United States;(7)., Pfizer Healthcare India Pvt. Ltd, Chennai, India;(8)., Pfizer Canada, Kirkland, Canada;(9)Farncombe Family Digestive Health Research Institute- McMaster University, Division of Gastroenterology- Department of Medicine, Hamilton- ON, Canada;
P798: Study of the concordance between the enzymatic activity of Thiopurine S-methyltransferase and polymorphisms in the TPMT gene in patients with Inflammatory Bowel DiseaseECCO'24Year: 2024
Authors: Céspedes Martínez, E.(1)*;Robles-Alonso, V.(1);Castellote , L.(2);Bravo-Nieto, D.(2);Serra , X.(1);Herrera-De Guise, C.(1);Mayorga, L.(1);Pérez, Z.(1);Oller, E.(1);Garriga-Edo, S.(2);Casellas, F.(1);Borruel, N.(1);
(1)Hospital Universitario Vall d@E@Hebron, Unitat d@E@Atenció Crohn-Colitis UACC- Gastroenterology Department, Barcelona, Spain;(2)Hospital Universitario Vall d@E@Hebron, Biochemistry Department, Barcelona, Spain;
P802: Impact of early use of immunomodulator on the outcomes of Crohn@E@s disease: A Systematic Review and Meta-AnalysisECCO'24Year: 2024
Authors: Yoo, J.H.(1)*;Yoon , J.(2);Jun , Y.K.(3);Lee , H.S.(4);ParkAssistant professor, J.J.(5);
(1)CHA Bundang Medical Center- CHA University School of Medicine, Gastroenterology, Seongnam, Korea- Republic Of;(2)Kangdong Sacred Heart Hospital, Internal Medicine, Seoul, Korea- Republic Of;(3)Seoul National University Bundang Hospital, Internal Medicine, Seoul, Korea- Republic Of;(4)Yonsei University College of Medicine, Biostatics Collaboration Unit, Seoul, Korea- Republic Of;(5)Severance Hospital- Yonsei University College of Medicine, Internal Medicine, Seoul, Korea- Republic Of;
P803: iGenoMed-MTT: A prospective multiomic study of response to molecularly targeted therapies in IBD.ECCO'24Year: 2024
Authors: Battat, R.(1)*;Boucher, G.(2);Thompson Legault, J.(2);Mercier, V.(2);Bitton, A.(3);Rioux, J.(2);
(1)University of Montreal, Gastroenterology and Hepatology, Montreal, Canada;(2)Montreal Heart Institute, Genetics, Montreal, Canada;(3)McGill University Health Centre, Gastroenterology, Montreal, Canada;
P804: Does Crohn@E@s disease extent and behavior have an impact on ustekinumab effectiveness? A real-world multicenter retrospective studyECCO'24Year: 2024
Authors: Samarentsis, N.(1);Kapizioni, C.(1)*;Georgakopoulou, N.(2);Michalopoulos, G.(2);Striki, A.(2);Karoumpalis, I.(2);Kartsoli, S.(3);Mellos, A.(3);Vrakas, S.(3);Vougadiotis, I.(3);Neonaki, A.(4);Karatzas, P.(4);Tsiamperas, N.(5);Kourikou, A.(5);Siakavellas, S.(5);Polymeros, D.(1);Manolakopoulos, S.(5);Papatheodoridis, G.(4);Triantafyllou, K.(1);
(1)Attikon University Hospital, Hepatogastroenterology Unit- 2nd Academic Department of Internal Medicine, Athens, Greece;(2)General Hospital @D@G.Gennimatas@D@, Department of Gastroenterology, Athens, Greece;(3)Tzaneio General Hospital, Department of Gastroenterology, Piraeus, Greece;(4)Laiko General Hospital, Department of Gastroenterology, Athens, Greece;(5)Hippocration General Hospital, Hepatogastroenterology Unit- 2nd Academic Department of Internal Medicine, Athens, Greece;
P805: The persistence of subcutaneous infliximab is equivalent to intravenous form in patients with inflammatory bowel diseases.ECCO'24Year: 2024
Authors: Bothorel, L.(1);Laharie, D.(1);Poullenot, F.(1);Gohier, E.(1);Chevrier, C.(1);Berger, A.(1);Zerbib, F.(1);Riviere, P.(1)*;
(1)Bordeaux University Hospitals, Gastroenterology department, Bordeaux, France;
P807: HLA type impact on immunization and efficacy of ustekinumab in IBD patients: a multicenter studyECCO'24Year: 2024
Authors: Delmeule, A.(1)*;Dubois, V.(2);gay, C.(1);Roblin, X.(3);Paul, S.(3);Nancey, S.(1);Boschetti, G.(1);
(1)CHU de Lyon, rhone, Lyon, France;(2)EFS, Rhone, Décines, France;(3)CHU de saint etienne, loire, saint etienne, France;
P808: Use of intestinal ultrasound influences the proportion of suboptimally controlled patients: IBD Podcast Study resultsECCO'24Year: 2024
Authors: Dignass, A.(1)*;D@E@Amico, F.(2);Gomollón, F.(3);Bamias, G.(4);Heatta-Speicher, T.(5);Michelena, N.(6);Leitner, C.(7);Hammer, L.(8);Magro, F.(9);
(1)Agaplesion Markus Hospital, Department of Medicine I, Frankfurt am Main, Germany;(2)IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Gastroenterology and Endoscopy, Milan, Italy;(3)Universitario Lozano Blesa, Hospital Clínico, Zaragoza, Spain;(4)Sotiria Hospital- National & Kapodistrian University of Athens, GI-Unit- 3rd Academic Dpt. Of Internal Medicine, Athens, Greece;(5)AbbVie AS, Immunology, Oslo, Norway;(6)AbbVie Spain- SLU, Immunology, Madrid, Spain;(7)AbbVie Switzerland, Immunology, Cham, Switzerland;(8)AbbVie Deutschland GmbH & Co. KG, Immunology, Wiesbaden, Germany;(9)Faculdade de Medicina da Universidade do Porto, CINTESIS@RISE Departament, Porto, Portugal;on behalf of the IBD-Podcast study group
P809: VARIETY BEACH: Real-world treatment patterns for vedolizumab intravenous and subcutaneous maintenance dosing observed over 1 year in studies from Belgium, Austria and Switzerland.ECCO'24Year: 2024
Authors: Novacek, G.(1)*;Hrúz, P.(2);Högenauer, C.(3);Louis, E.(4);Vavricka, S.R.(5,6);Moschen, A.R.(7);Biedermann, L.(5);Mächler, C.(8);Stemberger, B.(9);Van Gassen, G.(10);Baert, F.(11);
(1)Medical University of Vienna, Department of Internal Medicine III, Vienna, Austria;(2)Clarunis Universitäres Bauchzentrum, Department of Gastroenterology and Hepatology, Basel, Switzerland;(3)Medical University Graz, Department of Gastroenterology and Hepatology, Graz, Austria;(4)University Hospital CHU of Liège, Department of Gastroenterology, Liège, Belgium;(5)University Hospital Zürich, Department of Gastroenterology and Hepatology, Zürich, Switzerland;(6)Center for Gastroenterology and Hepatology, Department of Gastroenterology and Hepatology, Zürich, Switzerland;(7)Johannes Kepler University Faculty of Medicine, Department of Internal Medicine 2, Linz, Austria;(8)Takeda Pharma AG, Gastroenterology, Glattpark, Switzerland;(9)Takeda Ges.m.b.H, Gastroenterology, Vienna, Austria;(10)Takeda Belgium NV, Gastroenterology, Brussels, Belgium;(11)AZ Delta, Department of Gastroenterology, Roeselare, Belgium;
P810: Fecal microbiota transplantation in Ulcerative rectocolitisECCO'24Year: 2024
Authors: Ferreira, F.(1)*;Sousa, M.(2);Melado , M.(2);Pacheco, M.(3);Trindade, L.(3);Lorentz, F.(3);Carmo, L.(3);Clara, A.(3);
(1)Hospital da Santa Casa de Micericórdia de Vitória, Gastroenterology, Vitoria, Brazil;(2)Escola Superior de Ciências da Santa Casa de Misericórdia de Vitória, Medicine, Vitória, Brazil;(3)Hospital da Santa Casa de Misericórdia de Vitória, Gastroenterology, Vitória, Brazil;
